585-Drivers of Gastric Cancer Response to Immunochemotherapy скачать в хорошем качестве

585-Drivers of Gastric Cancer Response to Immunochemotherapy

This research article investigates biomarkers and cellular ecosystems that influence how gastric cancer patients respond to perioperative immunotherapy and chemotherapy. By analyzing data from the NEOSUMMIT-01 clinical trial, the authors identified specific genetic factors, such as HLA-B and LRP1B mutations, that serve as predictors for treatment success. The study categorizes the tumor microenvironment into five distinct ecotypes, ranging from immune-active zones that favor recovery to immunosuppressive regions that resist therapy. A critical discovery involves APOA1+ tumor cells, which appear to drive resistance by signaling TREM2+ macrophages to adopt a suppressive state. These findings suggest that targeting these metabolic and immune interactions could improve the effectiveness of treatments for locally advanced gastric cancer. References: • Zhao Q, Huang R, Wang C, et al. Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer[J]. Cancer Cell, 2026.